KR20160097290A - 펩타이드 혼합물 - Google Patents
펩타이드 혼합물 Download PDFInfo
- Publication number
- KR20160097290A KR20160097290A KR1020167018341A KR20167018341A KR20160097290A KR 20160097290 A KR20160097290 A KR 20160097290A KR 1020167018341 A KR1020167018341 A KR 1020167018341A KR 20167018341 A KR20167018341 A KR 20167018341A KR 20160097290 A KR20160097290 A KR 20160097290A
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- ras protein
- peptides
- mutation
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196333.2 | 2013-12-09 | ||
| EP13196333 | 2013-12-09 | ||
| PCT/EP2014/077033 WO2015086590A2 (en) | 2013-12-09 | 2014-12-09 | A peptide mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160097290A true KR20160097290A (ko) | 2016-08-17 |
Family
ID=49765823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167018341A Withdrawn KR20160097290A (ko) | 2013-12-09 | 2014-12-09 | 펩타이드 혼합물 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9775892B2 (enExample) |
| EP (5) | EP3363458A3 (enExample) |
| JP (2) | JP6781403B2 (enExample) |
| KR (1) | KR20160097290A (enExample) |
| CN (1) | CN105980403A (enExample) |
| AU (2) | AU2014363643B2 (enExample) |
| BR (1) | BR112016013138A2 (enExample) |
| CA (1) | CA2933126A1 (enExample) |
| CL (4) | CL2016001405A1 (enExample) |
| CY (1) | CY1120578T1 (enExample) |
| DK (1) | DK3079715T3 (enExample) |
| ES (1) | ES2682038T3 (enExample) |
| HR (1) | HRP20181213T1 (enExample) |
| HU (1) | HUE039840T2 (enExample) |
| IL (1) | IL246007B2 (enExample) |
| LT (1) | LT3079715T (enExample) |
| MX (1) | MX2016007429A (enExample) |
| PL (1) | PL3079715T3 (enExample) |
| PT (1) | PT3079715T (enExample) |
| RS (1) | RS57623B1 (enExample) |
| RU (1) | RU2016127327A (enExample) |
| SG (2) | SG11201604644QA (enExample) |
| SI (1) | SI3079715T1 (enExample) |
| WO (1) | WO2015086590A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210032393A (ko) * | 2018-06-19 | 2021-03-24 | 바이오엔테크 유에스 인크. | 신생항원 및 이의 용도 |
| KR20220091718A (ko) | 2020-12-24 | 2022-07-01 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3079715T (pt) | 2013-12-09 | 2018-08-02 | Targovax Asa | Uma mistura de péptidos |
| KR20170002563A (ko) | 2014-05-06 | 2017-01-06 | 타르고바스 에이에스에이 | 돌연변이 ras 펩타이드를 포함하는 펩타이드 백신 및 화학 요법제 |
| EP3576780A1 (en) * | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| EP3641807A4 (en) * | 2017-06-22 | 2021-04-21 | The Westmead Institute For Medical Research | Adoptive t cell therapy 2 |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| KR20210049119A (ko) * | 2018-08-22 | 2021-05-04 | 프레드 헛친슨 켄서 리서치 센터 | Kras 또는 her2 항원을 표적으로 하는 면역요법 |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| MX2021012004A (es) * | 2019-03-30 | 2021-11-04 | Biontech Us Inc | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. |
| WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
| WO2021087840A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| EP4293043A4 (en) * | 2021-02-10 | 2025-09-10 | Shanghai Genbase Biotechnology Co Ltd | EPITOPE PEPTIDE OF THE RAS G13D MUTANT AND T LYMPHOCYTE RECEPTOR RECOGNIZING THE RAS G13D MUTANT |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2023220434A2 (en) * | 2022-05-12 | 2023-11-16 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| EP4622664A1 (en) * | 2022-11-22 | 2025-10-01 | Elixirgen Therapeutics, Inc. | Antigens for cancer immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| KR101241272B1 (ko) | 2002-12-16 | 2013-03-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 면역 요법으로서의 효모계 백신 |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| EP2004666B1 (en) * | 2006-03-27 | 2014-09-03 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| PT3079715T (pt) | 2013-12-09 | 2018-08-02 | Targovax Asa | Uma mistura de péptidos |
| KR20170002563A (ko) | 2014-05-06 | 2017-01-06 | 타르고바스 에이에스에이 | 돌연변이 ras 펩타이드를 포함하는 펩타이드 백신 및 화학 요법제 |
-
2014
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en not_active Withdrawn
- 2014-12-09 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2014-12-09 US US15/102,681 patent/US9775892B2/en not_active Expired - Fee Related
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Withdrawn
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en not_active Ceased
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en not_active Withdrawn
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en not_active Withdrawn
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en not_active Ceased
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
-
2016
- 2016-06-02 IL IL246007A patent/IL246007B2/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en not_active Ceased
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210032393A (ko) * | 2018-06-19 | 2021-03-24 | 바이오엔테크 유에스 인크. | 신생항원 및 이의 용도 |
| KR20220091718A (ko) | 2020-12-24 | 2022-07-01 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019201937B2 (en) | A peptide mixture | |
| KR20180021072A (ko) | Ras 단백질의 변이된 단편 | |
| Guo et al. | Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity | |
| JP5787752B2 (ja) | 抗腫瘍免疫療法 | |
| Chen et al. | Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation | |
| Nelson et al. | Harnessing the microbiome to enhance cancer immunotherapy | |
| US20230287116A1 (en) | Chimeric antigen receptor cells targeting robo1, preparation method and use thereof | |
| US20190091310A1 (en) | Nonreleased il-12 for therapy of cancer | |
| JP2023517534A (ja) | Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質および抗癌剤を含む癌治療用薬学組成物 | |
| Wang et al. | Bortezomib inhibits bone marrow-derived dendritic cells | |
| CN103965360A (zh) | Ny-eso-1抗原及其在肿瘤免疫治疗中的应用 | |
| Botta et al. | New Immunotherapy Approaches for Preventing Cancer | |
| WO2024052542A2 (en) | A peptide cocktail | |
| Zhang et al. | Involvement of immune response in anti-tumor effects of Staphylococcus Aureus Filtrate Preparation | |
| Garcia et al. | Cancer immunology and novel strategies for immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160708 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |